Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.

Literature DB >> 20145660

Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.

Vincenzo Ficarra, Giacomo Novara.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2010 PMID： 20145660 DOI： 10.1038/nrurol.2010.2

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

10 in total

1. Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

3. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Authors: Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Journal: World J Urol Date: 2009-01-15 Impact factor: 4.226

4. Surgical resection of renal cell carcinoma after targeted therapy.

Authors: Anil A Thomas; Brian I Rini; Andrew J Stephenson; Jorge A Garcia; Amr Fergany; Venkatesh Krishnamurthi; Andrew C Novick; Inderbir S Gill; Eric A Klein; Ming Zhou; Steven C Campbell
Journal: J Urol Date: 2009-07-17 Impact factor: 7.450

5. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.

Authors: Chirag Amin; Eric Wallen; Raj S Pruthi; Benjamin F Calvo; Paul A Godley; W Kimryn Rathmell
Journal: Urology Date: 2008-08-05 Impact factor: 2.649

6. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal: J Urol Date: 2004-03 Impact factor: 7.450

7. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Authors: Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; David A Swanson; Eric Jonasch; Christopher G Wood
Journal: J Urol Date: 2008-05-15 Impact factor: 7.450

8. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.

Authors: Brian Shuch; Stephen B Riggs; Jeff C LaRochelle; Fairooz F Kabbinavar; Raffi Avakian; Allan J Pantuck; Jean-Jacques Patard; Arie S Belldegrun
Journal: BJU Int Date: 2008-04-10 Impact factor: 5.588

9. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245

10. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.

Authors: Pierre I Karakiewicz; Nazareno Suardi; Claudio Jeldres; Pascale Audet; Pierre Ghosn; Jean-Jacques Patard; Paul Perrotte
Journal: Eur Urol Date: 2007-11-20 Impact factor: 20.096

10 in total

6 in total

Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.

1. Sorafenib in advanced clear-cell renal-cell carcinoma.

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

3. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

4. Surgical resection of renal cell carcinoma after targeted therapy.

5. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.

6. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

7. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

8. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.

9. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

10. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.

1. Neoadjuvant targeted therapy in renal cell carcinoma.

2. [Systemic therapy of renal cell carcinoma].

3. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Review 4. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.

Review 5. Adjuvant and neoadjuvant therapy in renal cell carcinoma.

6. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.